Callisto Pharmaceuticals is a public biotechnology company that develops novel therapeutics to treat cancer. Synergy Pharmaceuticals, a wholly owned subsidiary of Callisto, is a private company that has a drug to treat gastrointestinal diseases. We source our drug candidates from breakthrough science, both internal and external. Our management has deep experience in drug development from both large pharmaceutical companies and smaller biotechnology companies. We pride ourselves on discovering and seeking out new or overlooked therapeutic approaches with the potential to improve the lives of large number of patients.

We currently have 3 drugs in development:

  • Atiprimod is an orally available small molecule drug that displays a multiplicity of anti-cancer mechanistic activities. The drug is presently in Phase II development for advanced carcinoid cancer and has potential in several other cancers, including liver and colon as well as mantle cell lymphoma.
  • L-Annamycin is a liposome nanoparticle formulation of annamycin, a second generation anthracycline. It has been developed to address shortcomings with the current generation of anthracycline drugs to treat relapsed or refractory acute leukemia patients. L-Annamycin has the potential to work against anthracycline-resistant tumors, is expected to have reduced cardiotoxicity. The compound is currently in Phase I/IIa trials for both adults and children with relapsed or refractory acute leukemia.

Callisto’s main office is located in Manhattan, New York, NY. Our laboratories are in Doylestown PA. The company is listed on the American Stock Exchange under the symbol KAL as well as on the Frankfurt Stock Exchange under the symbol CA4.